Esther Meijer

Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry

Edwin M. Spithoven, Anneke Kramer, Esther Meijer et al. · Nephrology Dialysis Transplantation · 2014 · 232 citations · Full text

Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype

Sarah R. Senum, Ying Li, Katherine A. Benson et al. · The American Journal of Human Genetics · 2021 · 151 citations · Full text

Urology, Autoimmune Disease, Medicine +12

Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study

Vicente E. Torres, Esther Meijer, Kyongtae T. Bae et al. · American Journal of Kidney Diseases · 2011 · 131 citations

Medicine, Kidney Failure, Renal Pathology +5

Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort

Esther Meijer, Stephan J. L. Bakker, Nynke Halbesma et al. · Kidney International · 2009 · 123 citations · Full text

Adrenal Gland, Renal Function, Large Population Cohort +6

Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease

Edwin M. Spithoven, Anneke Kramer, Esther Meijer et al. · Kidney International · 2014 · 120 citations · Full text

Urology, Renal Disease, Renal Function +7